Minako Ogawa-Tominaga

Minako Ogawa-Tominaga

Auto-generated profile, based on publicly available information

Minako Ogawa-Tominaga

Department of Metabolism, Chiba Children's Hospital, Chiba, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2020 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
PDF file
EOErika Ogawa
Erika Ogawa
TFTakuya Fushimi
Takuya Fushimi
MOMinako Ogawa‐Tominaga
Minako Ogawa‐Tominaga
MSMasaru Shimura
Masaru Shimura
MTMakiko Tajika
Makiko Tajika
KMKei Murayama
Kei Murayama
Leigh syndrome is a major phenotype of mitochondrial diseases in children. With new therapeutic options being proposed, assessing the mortality and clinical condition of Leigh syndrome patients is crucial for evaluating therapeutics. As data are scarce in Japan, we analysed the mortality rate and clinical condition of Japanese Leigh syndrome patients that we diagnosed since 2007. Data from 166 Japanese patients diagnosed with Leigh syndrome from 2007 to 2017 were reviewed. Patients' present status, method of ventilation and feeding, and degree of disability as of April 2018 was analysed. Overall, 124 (74.7%) were living, 40 (24.1%) were deceased, and 2 (1.2%) were lost to follow‐up. Median age of living patients was 8 years (1‐39 years). Median length of disease course was 91 months for living patients and 23.5 months for deceased patients. Nearly 90% of deaths occurred by age 6. Mortality rate of patients with onset before 6 months of age was significantly higher than that of onset after 6 months. All patients with neonatal onset were either deceased or bedridden. MT‐ATP6 deficiency caused by m.8993T>G mutation and MT‐ND5 deficiency induced a severe form of Leigh syndrome. Patients with NDUFAF6, ECHS1, and SURF1 deficiency had relatively mild symptoms and better survival. The impact of onset age on prognosis varied across the genetic diagnoses. The clinical condition of many patients was poor; however, few did not require mechanical ventilation or tube‐feeding and were not physically dependent. Early disease onset and genetic diagnosis may have prognostic value.

24 July 2020 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MSMasaru Shimura
Masaru Shimura
NKNaomi Kuranobu
Naomi Kuranobu
MOMinako Ogawa-Tominaga
Minako Ogawa-Tominaga
NANana Akiyama
Nana Akiyama
YSYohei Sugiyama
Yohei Sugiyama
KMKei Murayama
Kei Murayama
Background: Hepatocerebral mitochondrial DNA depletion syndrome (MTDPS) is a disease caused by defects in mitochondrial DNA maintenance and leads to liver failure and neurological complications during infancy. Liver transplantation (LT) remains controversial due to poor outcomes associated with extrahepatic symptoms. The purposes of this study were to clarify the current clinical and molecular features of hepatocerebral MTDPS and to evaluate the outcomes of LT in MTDPS patients in Japan. Results: We retrospectively assessed the clinical and genetic findings, as well as the clinical courses, of 23 hepatocerebral MTDPS patients from a pool of 999 patients who were diagnosed with mitochondrial diseases between 2007 and 2019. Causative genes were identified in 18 of 23 patients: MPV17 (n = 13), DGUOK (n = 3), POLG (n = 1), and MICOS13 (n = 1). Eight MPV17-deficient patients harbored c.451dupC and all three DGUOK-deficient patients harbored c.143-307_170del335. The most common initial manifestation was failure to thrive (n = 13, 56.5%). The most frequent liver symptom was cholestasis (n = 21, 91.3%). LT was performed on 12 patients, including nine MPV17-deficient and two DGUOK-deficient patients. Among the 12 transplanted patients, five, including one with mild intellectual disability, survived; while seven who had remarkable neurological symptoms before LT died. Five of the MPV17-deficient survivors had either c.149G > A or c.293C > T. Conclusions: MPV17 was the most common genetic cause of hepatocerebral MTDPS. The outcome of LT for MTDPS was not favorable, as previously reported, however, patients harboring MPV17 mutations associated with mild phenotypes such as c.149G > A or c.293C > T, and exhibiting no marked neurologic manifestations before LT, had a better prognosis after LT.

22 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MSMasaru Shimura
Masaru Shimura
NNNaoko Nozawa
Naoko Nozawa
MOMinako Ogawa-Tominaga
Minako Ogawa-Tominaga
TFTakuya Fushimi
Takuya Fushimi
MTMakiko Tajika
Makiko Tajika
KMKei Murayama
Kei Murayama
Mitochondrial respiratory chain complexes II, III, and IV and cytochrome c contain haem, which is generated by the insertion of Fe2+ into protoporphyrin IX. 5-Aminolevulinic acid (ALA) combined with sodium ferrous citrate (SFC) was reported to enhance haem production, leading to respiratory complex and haem oxygenase-1 (HO-1) upregulation. Here, we investigated the effects of different concentrations of ALA and SFC alone or in combination (ALA/SFC) on fibroblasts from 8 individuals with mitochondrial diseases and healthy controls. In normal fibroblasts, expression levels of oxidative phosphorylation (OXPHOS) complex subunits and corresponding genes were upregulated only by ALA/SFC. Additionally, the increased oxygen consumption rate (OCR) and ATP levels in normal fibroblasts were more obvious after treatment with ALA/SFC than after treatment with ALA or SFC. OXPHOS complex proteins were enhanced by ALA/SFC, whereas OCR and ATP levels were increased in 6 of the 8 patient-derived fibroblasts. Further, HO-1 protein and mRNA levels were enhanced by ALA/SFC in all fibroblasts. The relative mtDNA copy number was increased by ALA/SFC. Thus, our findings indicate that ALA/SFC is effective in elevating OXPHOS, HO-1 protein, and mtDNA copy number, resulting in an increase in OCR and ATP levels, which represents a promising therapeutic option for mitochondrial diseases.

7 October 2021 in Archives of Disease in Childhood - Fetal and Neonatal Edition
Verified
Journal Article
Open access
PDF file
TETomohiro Ebihara
Tomohiro Ebihara
TNTaro Nagatomo
Taro Nagatomo
YSYohei Sugiyama
Yohei Sugiyama
TTTomoko Tsuruoka
Tomoko Tsuruoka
YOYoshiteru Osone
Yoshiteru Osone
KMKei Murayama
Kei Murayama
Objective Neonatal-onset mitochondrial disease has not been fully characterised owing to its heterogeneity. We analysed neonatal-onset mitochondrial disease in Japan to clarify its clinical features, molecular diagnosis and prognosis. Design Retrospective observational study from January 2004 to March 2020. Setting Population based. Patients Patients (281) with neonatal-onset mitochondrial disease diagnosed by biochemical and genetic approaches. Interventions None. Main outcome measures Disease types, initial symptoms, biochemical findings, molecular diagnosis and prognosis. Results Of the 281 patients, multisystem mitochondrial disease was found in 194, Leigh syndrome in 26, cardiomyopathy in 38 and hepatopathy in 23 patients. Of the 321 initial symptoms, 236 occurred within 2 days of birth. Using biochemical approaches, 182 patients were diagnosed by mitochondrial respiratory chain enzyme activity rate and 89 by oxygen consumption rate. The remaining 10 patients were diagnosed using a genetic approach. Genetic analysis revealed 69 patients had nuclear DNA variants in 36 genes, 11 of 15 patients had mitochondrial DNA variants in five genes and four patients had single large deletion. The Cox proportional hazards regression analysis showed the effects of Leigh syndrome (HR=0.15, 95% CI 0.04 to 0.63, p=0.010) and molecular diagnosis (HR=1.87, 95% CI 1.18 to 2.96, p=0.008) on survival. Conclusions Neonatal-onset mitochondrial disease has a heterogenous aetiology. The number of diagnoses can be increased, and clarity regarding prognosis can be achieved by comprehensive biochemical and molecular analyses using appropriate tissue samples.

27 May 2020 in Brain
Verified
Journal Article
Closed access
NBNurun Nahar Borna
Nurun Nahar Borna
YKYoshihito Kishita
Yoshihito Kishita
Jiro AbeJiro Abe
Jiro Abe
TFTakuro Furukawa
Takuro Furukawa
MOMinako Ogawa-Tominaga
Minako Ogawa-Tominaga
YOYasushi Okazaki
Yasushi Okazaki

7 February 2019 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
KHKeiichi Hirono
Keiichi Hirono
FIFukiko Ichida
Fukiko Ichida
NNNatsuhito Nishio
Natsuhito Nishio
MOMinako Ogawa‐Tominaga
Minako Ogawa‐Tominaga
TFTakuya Fushimi
Takuya Fushimi
KMKei Murayama
Kei Murayama
Key Clinical Message: We identified novel compound heterozygous TMEM70 variants in a Japanese patient who had hyperlactacidemia, metabolic acidosis, hyperalaninemia, developmental delay, undescended testicle, and left ventricular noncompaction. The urinary organic acids profile revealed elevated levels of 3‐ MGA , and BN ‐ PAGE /Western blotting analysis and ETC. activity confirmed complex V deficiency.